(Source: Datamonitor)
Teva Pharmaceutical Industries, an Israeli generic pharmaceutical company, and its partner, Antares Pharma, a product development company, have received approval for a supplemental new drug application, which added 'needle-free injection' to its Tev-Tropin brand human growth hormone drug label.
Teva will market the Antares needle-free device as the Tev-Tropin Tjet injector system. Tev-Tropin is indicated only for the treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone.
Larry Downey, head of Teva's North America brand pharmaceuticals division, said: "We are pleased to add this new technology to our growing portfolio through our successful partnership with Antares, and to offer patients a less invasive delivery system.
"This significant achievement demonstrates our ability to leverage our leadership in the pharmaceutical industry, and our ongoing commitment to utilize our global strengths in innovative activities."
A service of YellowBrix, Inc.
